SCHEMBL5215264

SCHEMBL5215264

NC(=O)N1CCC(O)CC1.O=C(O)CNc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP2D6 P10635 1/20 0.44
OPRK1 P41145 1/20 0.44
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GRM5 P41594 1/20 0.42
PIN1 Q13526 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
EGLN1 Q9GZT9 1/20 0.41
FAAH O00519 1/20 0.41
YAP1 P46937 1/20 0.40
TEAD4 Q15561 1/20 0.40
NAMPT P43490 1/20 0.40
ATM Q13315 1/20 0.39
TP53 P04637 1/20 0.39
EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984072 0.85 KDM4E (0.43) KDM4ESMN1; SMN2EGLN1EPHX2
SCHEMBL6214071 0.82 ALDH1A1 (0.51) KDM4EMAPTLMNAGAAL3MBTL1
SCHEMBL5210299 0.81 KDM4E (0.38) KDM4EMAPTLMNAGAAL3MBTL1
Urea SCHEMBL7646273 0.78 ABAT (0.48) KDM4EMAPTLMNAGAANPC1
Carbamic Acid SCHEMBL754112 0.78 ABAT (0.48) KDM4EMAPTLMNAGAAL3MBTL1
SCHEMBL8118829 0.77 LMNA (0.53) MAPTLMNAGAAL3MBTL1GRM5
SCHEMBL8304517 0.77 CYP2D6 (0.51) KDM4EMAPTLMNAGAAL3MBTL1
Hydrazine SCHEMBL2403240 0.76 ABAT (0.50) KDM4EMAPTLMNAGAAL3MBTL1
Hydrochloric Acid SCHEMBL3069393 0.76 ABAT (0.53) KDM4EMAPTLMNAGAAL3MBTL1
SCHEMBL1330698 0.76 ABAT (0.53) KDM4EMAPTLMNAGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed
EP-1240154-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2002-09-18 EP disclosed
EP-1192135-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-04-03 EP disclosed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 WO disclosed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 KDM4E 2460/4885MAPT 4112/4885LMNA 563/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 KDM4E 2148/4885MAPT 4440/4885LMNA 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.